These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24282149)

  • 1. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
    Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
    Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
    Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.
    Zhang S; Hou C; Li G; Zhong Y; Zhang J; Guo X; Li B; Bi Z; Shao M
    Int J Mol Med; 2016 Sep; 38(3):919-26. PubMed ID: 27430246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
    Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
    Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
    Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
    Langevin SM; Christensen BC
    Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
    Luong HT; Nyholt DR; Painter JN; Chapman B; Kennedy S; Treloar SA; Zondervan KT; Montgomery GW
    Hum Reprod; 2012 Dec; 27(12):3616-21. PubMed ID: 23010532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
    Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
    Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
    Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
    PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
    Kazmi HR; Chandra A; Kumar S; Satyam LK; Gupta A; Nigam J; Srivastava M; Mittal B
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2577-2583. PubMed ID: 27620744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cell line model for cancer-associated KRAS noncoding SNP.
    Lauring J
    Hum Mutat; 2014 Feb; 35(2):v. PubMed ID: 24415639
    [No Abstract]   [Full Text] [Related]  

  • 13. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.
    Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ
    Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.
    Hu H; Zhang L; Teng G; Wu Y; Chen Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1641-9. PubMed ID: 26316738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
    Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
    Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-mediated regulation of KRAS in cancer.
    Kim M; Slack FJ
    J Hematol Oncol; 2014 Nov; 7():84. PubMed ID: 25433809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
    Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
    Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
    Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
    Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer.
    Lyu S; Yu Q; Ying G; Wang S; Wang Y; Zhang J; Niu Y
    Int J Oncol; 2014 Jan; 44(1):229-37. PubMed ID: 24172884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
    Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
    Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.